Tryp Therapeutics Inc.

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
89854F106
SEDOL
N/A
CIK
N/A
tryptherapeutics.com
LEI:
©
New: Infographics X-Lab
FIGI: -
TRYP
Tryp Therapeutics Inc.
GICS: - · Sektor: - · Sub-Sektor: -
AI
PROFILER
NAME
Tryp Therapeutics Inc.
ISIN
CA89854F1062
TICKER
TRYP
MIC
XCNQ
REUTERS
TRYP.TO
BLOOMBERG
TRYP CN
F&G: 35
1,38547 USDCAD · 95.004,71 BTC · 23,48 Vola-Index · 19.434,70 Tech100
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von Newsfile Corp. bereitgestellt.
Fr., 17.05.2024       Tryp Therapeutics
CA89854F1062

Kelowna, British Columbia--(Newsfile Corp. - May 17, 2024) - Tryp Therapeutics, Inc. (CSE: TRYP) ("Tryp" or the "Company") announces, that it has filed amended financial statements for the six months ended February 29, 2024 (the "Financial Statements"), along with the corresponding Management Discussion & Analysis (the "MD&A"). The amendmen...
Zur Nachricht
Tryp Therapeutics
Technische Analyse Termsheet Terminal
Permalink
Do., 04.11.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - Donnerstag, 4. November 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" oder das "Unternehmen"), ein Pharmaunternehmen mit Fokus auf der Entwicklung von Psilocybin-basierten Verbindungen für Krankheiten mit ungedecktem medizinischem Bedarf, gab heute bekannt, dass es einen Antrages für...
Zur Nachricht
Tryp Therapeutics
Technische Analyse Termsheet Terminal
Permalink
Do., 04.11.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - November 4, 2021) - - Nov. 4, 2021 - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that the Company will participate in Wonderland: Miami, presented by M...
Zur Nachricht
Tryp Therapeutics
Technische Analyse Termsheet Terminal
Permalink
Di., 02.11.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - November 2, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug ("IND") application to the U.S. Food a...
Zur Nachricht
Tryp Therapeutics
Technische Analyse Termsheet Terminal
Permalink
Di., 26.10.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - October 26, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the Company will present at the 15th Annual Pain Therapeutics Summit on November 1,...
Zur Nachricht
Tryp Therapeutics
Technische Analyse Termsheet Terminal
Permalink
Do., 21.10.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - October 20, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") has placed a clinical hold on the Com...
Zur Nachricht
Tryp Therapeutics
Technische Analyse Termsheet Terminal
Permalink
Do., 14.10.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - October 14, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today its inclusion in the AdvisorShares Psychedelics ETF (the "Fund"), currently trading under the ticker symb...
Zur Nachricht
Tryp Therapeutics
Technische Analyse Termsheet Terminal
Permalink
Di., 12.10.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - October 12, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present at the KCSA Psychedelics Virtual Investor Conference on October 14, 2021 at 3:...
Zur Nachricht
Tryp Therapeutics
Technische Analyse Termsheet Terminal
Permalink
Do., 07.10.2021       Tryp Therapeutics
CA89854F1062

Tryp has partnered with Paul Hutson, PharmD and Christopher Nicholas, PhD to advance the Company's proprietary, psilocybin-based drug productSan Diego, California--(Newsfile Corp. - October 7, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for...
Zur Nachricht
Tryp Therapeutics
Technische Analyse Termsheet Terminal
Permalink
Mi., 22.09.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - Mittwoch, 22. September 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), ein Pharmaunternehmen mit Fokus auf der Entwicklung von Psilocybin-basierten Verbindungen für Krankheiten mit ungedecktem medizinischem Bedarf, gab heute seine Einreichung eines Investigational New Drug (" IND ")-Antr...
Zur Nachricht
Tryp Therapeutics
Technische Analyse Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S